FDA Approves Large Studies of Ecstasy to Treat PTSD
Large-scale Phase 3 clinical trials of the illegal party drug Ecstasy as a treatment for post-traumatic stress disorder (PTSD) were approved Tuesday by the U.S. Food and Drug Administration.
Some small studies have yielded promising results. If the new trials are successful, Ecstasy (MDMA) could be approved as a prescription drug for PTSD, The New York Times reported.
An FDA spokeswoman declined to comment on the matter, citing rules that forbid providing information about drugs under development.
Click here to Read the full article: FDA Approves Large Studies of Ecstasy to Treat PTSD
Share this entry
- National Epilepsy Awareness Month November 21, 2017
- American Health Council Names Paul M. Colombani, MD, FACS, FAAP to Education Board November 21, 2017
- The American Health Council Appoints Jennifer Bouchard, ANP, to its Board of Nurses November 20, 2017
- Cassie Banks, BSN, MS-FNP, DNP Elected by American Health Council to Board of Nurses November 20, 2017
- American Health Council Welcomes Anikar Chhabra, MD, MS to Physician Board November 17, 2017
- The American Health Council Education Board Welcomes Carol Delville PhD, RN, ACNS-BC November 16, 2017